Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Cameron grandmother calls for Maytag oven recall after her stove explodes
Recommended
Map shows parts of western NC open for tourism
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Viridian Therapeutics Inc
(NQ:
VRDN
)
22.28
+0.71 (+3.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Viridian Therapeutics Inc
< Previous
1
2
3
4
Next >
Analyst Expectations For Viridian Therapeutics's Future
October 28, 2024
Via
Benzinga
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
September 26, 2024
Via
Benzinga
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
September 10, 2024
Via
Benzinga
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
September 10, 2024
Via
Benzinga
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival
September 10, 2024
The results are also promising for the next-generation version of that drug.
Via
Investor's Business Daily
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety
September 10, 2024
Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroid eye disease meeting all primary and secondary endpoints. Viridian plans...
Via
Benzinga
Exposures
Product Safety
Decoding 6 Analyst Evaluations For Viridian Therapeutics
August 15, 2024
Via
Benzinga
Expert Ratings For Viridian Therapeutics
July 16, 2024
Via
Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
September 10, 2024
Via
Benzinga
VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Top 3 Health Care Stocks You May Want To Dump This Quarter
July 30, 2024
Via
Benzinga
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
July 16, 2024
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Via
Investor's Business Daily
3 Small-Cap Stocks With Explosive 2X Growth Potential
July 08, 2024
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.
Via
InvestorPlace
7 Analysts Assess Viridian Therapeutics: What You Need To Know
June 06, 2024
Via
Benzinga
Unveiling 4 Analyst Insights On Viridian Therapeutics
March 20, 2024
Via
Benzinga
Navigating 6 Analyst Ratings For Viridian Therapeutics
February 28, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 11, 2024
Via
Benzinga
VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
March 19, 2024
Although cheap stocks under $20 represent a higher-risk profile, the rewards could be massive if the spotlight shines on them.
Via
InvestorPlace
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
January 18, 2024
Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering.
Via
Benzinga
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday
December 18, 2023
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Analyst Ratings for Viridian Therapeutics
December 04, 2023
Via
Benzinga
Where Viridian Therapeutics Stands With Analysts
November 14, 2023
Via
Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Stocks That Hit 52-Week Lows On Tuesday
October 03, 2023
On Tuesday, 647 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 28, 2023
During Thursday's session, 406 companies made new 52-week lows.
Via
Benzinga
Analyst Ratings for Viridian Therapeutics
September 13, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 26, 2023
On Tuesday, 386 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
During the session on Thursday, 461 stocks hit new 52-week lows.
Via
Benzinga
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
August 10, 2023
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.